Drugs / CNTO 5825
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01081691 | Feb → Sep 2010 | — | Centocor, Inc. | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CNTO 5825 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01081691 ↗ |
| Action | Inhibit | “Interleukin-13 inhibitor” CHEMBL2109464 ↗ |
| Modality | Monoclonal antibody | “A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers” NCT01081691 ↗ |
| Route | Intravenous | “single intravenous (IV) or subcutaneous (SC) dose administration” NCT01081691 ↗ |
| Route | Subcutaneous | “single intravenous (IV) or subcutaneous (SC) dose administration” NCT01081691 ↗ |
| Target | IL13 | “Interleukin-13 inhibitor” CHEMBL2109464 ↗ |